Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 15/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 10/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 10/20 | 0.40 |
| ▸ | CCND1 | P24385 | 10/20 | 0.40 |
| ▸ | RPS6KA2 | Q15349 | 4/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.39 |
| ▸ | CCND3 | P30281 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4549860 | 0.82 | CDK2 (0.56) | CDK2CCNE1CDK4CCND1CCNT1 | |
| SCHEMBL15249224 | 0.81 | CDK2 (0.57) | CDK2CCNE1CDK4CCND1CCNT1 | |
| SCHEMBL31252716 | 0.81 | CDK2 (0.57) | CDK2CCNE1CDK4CCND1CCNT1 | |
| SCHEMBL18637773 | 0.76 | CDK2 (0.55) | CDK2CCNE1CDK4CCND1CCNT1 | |
| SCHEMBL18638033 | 0.74 | CDK2 (0.53) | CDK2CCNE1CDK4CCND1CDK6 | |
| SCHEMBL15298151 | 0.74 | CDK2 (0.53) | CDK2CCNE1CDK4CCND1CDK6 | |
| SCHEMBL4549832 | 0.72 | CDK4 (0.50) | RPS6KA3CDK4CCND1 | |
| SCHEMBL20959562 | 0.72 | CCNE1 (0.39) | CDK2CCNE1CDK4CCND1CCNT1 | |
| SCHEMBL18573359 | 0.71 | RPS6KA3 (0.50) | RPS6KA3RPS6KA2 | |
| SCHEMBL23016499 | 0.70 | RPS6KA3 (0.48) | RPS6KA3CDK4CCND1RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-8822683-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140142306-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142306-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142299-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142299-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2013148748-A1 | LACTAM KINASE INHIBITORS | TAVARES FRANCIS XAVIER (US) | 2013-10-03 | — | — | WO | disclosed |
| US-20130237544-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237544-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237534-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | CDK2 5/4885CCNE1 31/4885RPS6KA3 312/4885 |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | CDK2 13/4885CCNE1 72/4885RPS6KA3 129/4885 |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | CDK2 69/4885CCNE1 58/4885RPS6KA3 1145/4885 |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | CDK2 10/4885CCNE1 42/4885RPS6KA3 342/4885 |
| US-20140142306-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | CDK2 5/4885CCNE1 31/4885RPS6KA3 312/4885 |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | CDK4, RB1, BTK | CDK2 16/4885CCNE1 75/4885RPS6KA3 243/4885 |
| US-20140142299-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | CDK2 5/4885CCNE1 31/4885RPS6KA3 312/4885 |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | CDK2 10/4885CCNE1 42/4885RPS6KA3 342/4885 |
| US-20130237544-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | CDK2 5/4885CCNE1 31/4885RPS6KA3 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.